adalimumab-aqvh 40 MG per 0.8 ML Prefilled Syringe

RxCUI: 2640389
RxNorm name: adalimumab-aqvh 40 MG per 0.8 ML Prefilled Syringe
Display name: adalimumab-aqvh 40 MG per 0.8 ML Prefilled Syringe
Full name: adalimumab-aqvh 40 MG per 0.8 ML Prefilled Syringe
Term type: SY
Status: DailyMed mapping
Updated: 2026-06-04 23:39:21

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLA	Proprietary name	Proper name	License type	Status	Latest source
761216	Yusimry	adalimumab-aqvh	351(k) Biosimilar	Rx	2026-07-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 2 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
YUSIMRY	ADALIMUMAB-AQVH	Meitheal Pharmaceuticals Inc.	4cab600d-6950-409f-a6d8-d447da22cd95	2025-10-31	Boxed warning, Warnings, Adverse reactions	Exact identifier rxcui: 2640389
YUSIMRY	ADALIMUMAB-AQVH	Coherus BioSciences Inc	cd0e7af2-7704-49ce-bde9-f645294b6788	2025-05-16	Boxed warning, Warnings, Adverse reactions	Exact identifier rxcui: 2640389

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 2 matching rows.

Set ID, RxNorm mappings, Terms table
Set ID	RxNorm mappings	Terms	SPL version	Label	Effective
4cab600d-6950-409f-a6d8-d447da22cd95	adalimumab-aqvh 40 MG in 0.8 ML Prefilled Syringe [PSN] · 0.8 ML adalimumab-aqvh 50 MG/ML Prefilled Syringe [SCD] · adalimumab-aqvh 40 MG per 0.8 ML Prefilled Syringe [SY]	3	6	These highlights do not include all the information needed to use YUSIMRY safely and effectively. See full prescribing information for YUSIMRY. YUSIMRY (adalimumab-aqvh) injection, for subcutaneous use Initial U.S. Approval: 2021 YUSIMRY (adalimumab-aqvh) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences betwee	20251031
cd0e7af2-7704-49ce-bde9-f645294b6788	adalimumab-aqvh 40 MG in 0.8 ML Prefilled Syringe [PSN] · 0.8 ML adalimumab-aqvh 50 MG/ML Prefilled Syringe [SCD] · adalimumab-aqvh 40 MG per 0.8 ML Prefilled Syringe [SY]	3	6	These highlights do not include all the information needed to use YUSIMRY safely and effectively. See full prescribing information for YUSIMRY. YUSIMRY (adalimumab-aqvh) injection, for subcutaneous use Initial U.S. Approval: 2021 YUSIMRY (adalimumab-aqvh) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences betwee	20250516